Otros idiomas Immutep ADR Nasdaq

Acciones

IMMP

US45257L1089

Tiempo real estimado Cboe BZX Otros sitios de cotización 21:15:07 21/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3,32 ^USD	+7,10 %		+11,60 %	+36,25 %

17/05	IMMUTEP ADR : Actualizado por Capital One Securities	ZM
15/05	Immutep afirma que la fase inicial de seguridad de un estudio sobre el cáncer de mama arroja datos "alentadores	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	15/05
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	15/05
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	15/05
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02/05
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	30/04
Immutep Quarterly Activities Report Q3 FY24	29/04
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	25/04
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	24/04
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24/04
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18/04
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	18/04
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18/04
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	18/04
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18/04
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	17/04
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	17/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Immutep ADR Nasdaq

Acciones

IMMP

US45257L1089

Otros idiomas

Filtros